• Journal of Chest Surgery
• /
• 제37권12호
• /
• pp.1003-1009
• /
• 2004

기계적 순환 보조는 만성 심부전 상태의 환자들에게 이용될 뿐만 아니라, 심정지 혹은 심인성 쇼크에서 생명을 구할 수 있는 필수적인 요소가 되기도 한다. 상용화된 다양한 박동형의 순환보조 장치들이 장기간의 좌심실 보조를 위해 사용될 수 있지만 비용이나 제조사로부터의 기술적 지원이라는 측면에서 그 사용에 제약이 되고있다. 최근에는 심장이식의 가교로서, 또는 심장회복을 위해 원심성 펌프를 단기간 사용한 예들이 보고되고 있다. 본원에서는 원심형 펌프를 이용한 체외 생명구조 장치나 좌심실 보조장치로 심정지 혹은 심인성 쇼크의 5명의 환자에게 적용하여 성공적으로 치료하였다. 이들중 2명이 허혈성 심질환에 의한 심정지로 응급 상황에서 시행되었고, 술 후 심인성 쇽을 보인 허혈성 질환 1예와 급성 바이러스성 심근염에 의한 저심박출량 증후군을 보인 2명은 예정 하에 수술하였다. 모든 환자에서 기계적 순환보조 이탈이 가능하였으며, 기계적 순환 보조와 관련된 합병증에는 출혈 및 급성 신부전등이 있었고 대퇴동, 정맥 캐눌라 삽관과 연관된 합병증은 없었다. 원심형 펌프를 이용한 기계적 순환보조는 심정지 혹은 심인성 쇼크에서 생명보존이나 유지에 필수적인 역할을 할 수 있으며 항시 고려해야할 요소로 판단되기에 이를 보고하는 바이다.

• 대한기계학회논문집B
• /
• 제30권1호
• /
• pp.87-94
• /
• 2006

This paper presents the hydrodynamic design and performance analysis method for a miniaturized centrifugal blood pump using three-dimensional computational fluid dynamics (CFD) code. In order to obtain the hydraulically high efficient configuration of a miniaturized centrifugal blood pump for cardiopulmonary circulation, a well-established commercial CFD code was incorporated considering detailed flow dynamic phenomena in the blood pump system. A prototype of centrifugal blood pump developed by the present design and analysis method has been tested in the mock circulatory system. Predicted results by the CFD code agree very well with in vitro hydraulic performance data for a centrifugal blood pump over the entire operating conditions. Preliminary in vivo animal testing has also been conducted to demonstrate the hemodynamic feasibility for use of centrifugal blood pump as a mechanical circulatory support. A miniaturized centrifugal blood pump developed by the hydraulic design optimization and performance prediction method presented herein shows the possibility of a good candidate for intra and extracorporeal cardiopulmonary circulation pump in the near future.

• 대한의용생체공학회:의공학회지
• /
• 제22권4호
• /
• pp.349-358
• /
• 2001

A novel electro-mechanical implantable ventricular assist system is developed as a bridge to transplantation or recovery for patients with end-stage heart failure. The developed system is composed of an implanted blood pump, an external monitoring system which stores data, and a wearable system including a portable external driver and a portable power supply system. The blood pump is designed to be implanted into the left upper abdominal space and provides blood flow from the left ventricular apex to the aorta. The pulsatile blood flow is generated by a double cylindrical cam. There was mo excessive heat emission from the blood pump into the temperature-controlled chamber in the heat test and no stagnated flow within the blood sac by the observation in the flow visualization test. Animal experiments were performed using sheep and calves. The maximum assist flow rate reached 7.85L/min in the animal experiment. The evaluation results showed that the developed system was feasible for the implantable ventricular assist system. The long-term in vitro durability test and mid-term in vivo experiments are in progress and mow the modified next model is under development.

• Journal of Chest Surgery
• /
• 제40권7호
• /
• pp.512-516
• /
• 2007

기계적인 순환보조장치는 급성호흡부전이나 심부전에서 생명을 구할 수 있는 방편의 하나이다. 현재 여러 가지 형태의 순환 보조장치가 있으며 Twin-Pulse Life Support (T-PLS) system은 박동형 펌퍼의 한 종류다. 3예의 심한 심폐기능부전 상태 환자에게 순환보조장치로 T-PLS system을 사용하였다. 적응증은 인공호흡기와 강심제를 최대한 사용함에도 불구하고 지속되는 호흡부전이나 심부전이었다. 감염에 의한 호흡부전환자가 2예, 심근염에 의한 심부전 환자가 1예였다. 각각 한 명의 호흡부전환자와 신부전 환자가 생존하였는데 보조장치의 사용시간은 각각 3일과 5일이었다. T-PLS system은 순환보조장치로 유용하게 사용할 수 있으며 다발성 장기부전이 오기 전에 적용하여야 할 것으로 생각된다.

• 대한기계학회:학술대회논문집
• /
• 대한기계학회 2008년도 추계학술대회A
• /
• pp.1679-1682
• /
• 2008

Pulsatile Extracorporeal Membrane Oxygenation(ECMO) can mitigate the heart load and raise the patient's blood perfusion. But If the ECMO pulsate the blood flow during the systolic period, It can burden to the patient's heart. To avoid the heart injury, we have to consider the relation between output of ECMO, hemodynamic states and heart movement. To raise the efficacy of the pulsatile ECMO, we investigated the coronary perfusion, cardiac muscle tension and hemodynamic states during the ECMO perfusion by using the mathematical model of human blood circulatory system and ECMO. The outflow data of the pulsatile ECMO(T-PLS, Bioheartkorea, Korea) was obtained in vitro experiments. According to the phase and pumping rate of the ECMO, the heart's load and coronary perfusion could be adjusted to the proper levels. The results of the human- ECMO lumped parameter model showed that the synchronizing operation of the pulsatile ECLS can be helpful at stabilizing the patient's hemodynamic states.

• 대한의용생체공학회:의공학회지
• /
• 제19권2호
• /
• pp.163-170
• /
• 1998

인공심장의 주된 합병증인 혈전과 감염의 문제를 줄이고 장착 환자의 삶의 질을 높이기 위하여 체내 완전 매립형 전기 유압식 인공심장을 개발하고 있는 것과 이 모델을 이용한 동물실험에 대하여 보고하는 바이다. 이 인공심장은 혈액펌프, 유압구동기, 구동제어회로, 경피적 에너지-정보 전송시스템, 체내 받테리 등으로 구성되어 있다. 실험동물은 체중 62Kg의 송아지를 이용하였다. 흉강내 이식하는데 어려움은 없었고, 수술 후 생존하는 동안 혈역학적으로 문제는 없었으며 특이한 합병증도 발생하지 않았다. 그러나 이식 11일째 기계적인 결함으로 작동이 정지하였다. 앞으로 기계적 수명이나 생체적 합성 등의 문제 등히 해결되어야 할 것이다.

• 한국화재소방학회논문지
• /
• 제24권5호
• /
• pp.142-149
• /
• 2010

심폐소생술이란 인공호흡과 순환보조를 통하여 조직으로의 산소 공급을 유지하여 임상적 사망에서 생물학적 사망으로 진행을 막고, 심장박동과 순환을 회복시켜 환자를 소생시켜주는 술기이다. 심폐소생술이 시행되더라도 모든 심장정지 환자가 소생되는 것은 아니며, 얼마나 신속하고 정확하게 심폐소생술이 시행되었느냐에 따라 환자의 생존률이 결정된다. 현장에서 심장정지가 목격되지 않은 환자는 병원이송 전 현장에서 2분간 5주기 심폐소생술을 수행하고 자동제세동기를 사용하도록 하였고, 목격된 환자에게는 즉시 자동제세동기를 사용할 것을 권장하고 있으며 이후 전문적인 심장구조술이 필요하다. 병원 전 단계에서 119 구급대가 이송한 환자 중 자발순환회복(return of spontaneous circulation, ROSC)되어 이송하는 경우와 전문심장구조술을 시행 하는 경우는 매우 드물다. 현장에서 심장정지가 목격되었으나 심폐소생술이 시행되지 않았고 구급대원이 도착한 후 심폐소생술 시행 및 전문심장구조술로 현장에서 자발순환회복되어 생존퇴원한 1례를 경험하여 문헌고찰과 함께 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제44권1호
• /
• pp.9-17
• /
• 2011

Background: A peripheral extracorporeal membrane oxygenator (p-ECMO) has been developed to support patients who are dying due to a serious cardiopulmonary condition. This analysis was planned to define the clinical situation in which the patient benefits most from a p-ECMO. Material and Methods: Between June 2007 and Aug 2009, a total of 41 adult patients used the p-ECMO. There were 23 males and 18 females (mean age $54.4{\pm}15.1$ years). All patients had very unstable vital signs with hypoxia and complex cardiac problems. We divided the patients into 4 groups. In the first group, a p-ECMO was used as a bridge to cardiac operation. In the second group, patients did not have the opportunity to undergo any cardiac procedures; nevertheless, they were treated with a p-ECMO. In the third group, patients mostly had difficulty in weaning from CPB (cardiopulmonary bypass) after cardiac operation. The fourth group suffered from many complications, such as pneumonia, bleeding, infections, and LV dysfunction with underlying cardiac problems. All cannulations were performed by the Seldinger technique or cutting down the femoral vessel. A long venous cannula of $DLP^{(R)}$ (Medtronic Inc, Minneapolis, MN) or $RMI^{(R)}$ (Edwards Lifesciences LLC, Irvine, CA) was used together with a 17~21 Fr arterial cannula and a 21 Fr venous cannula. As a bypass pump, a Capiox emergency bypass system ($EBS^{(R)}$; Terumo, Tokyo, Japan) was used. We attempted to maintain a flow rate of $2.4{\sim}3.0\;L/min/m^2$ and an activated clotting time (ACT) of around 180 seconds. Results: Nine patients survived by the use of the p-ECMO. Ten patients were weaned from a p-ECMO but they did not survive, and the remainder had no chance to be weaned from the p-ECMO. The best clinical situation to apply the p-ECMO was to use it as a bridge to cardiac operation and for weaning from CPB after cardiac operation. Conclusion: Various clinical results were derived by p-ECMO according to the clinical situation. For the best results, early adoption of the p-ECMO for anatomical correction appears important.

• Journal of Chest Surgery
• /
• 제45권5호
• /
• pp.295-300
• /
• 2012

Background: With growing attention to the aortopathy associated with aortic valve diseases, the number of candidates for accompanying ascending aorta and/or root replacement is increasing among the patients who require aortic valve replacement (AVR). However, such procedures have been considered more risky than AVR alone. This study aimed to compare the surgical outcome of isolated AVR and AVR combined with aortic procedures. Materials and Methods: A total of 86 patients who underwent elective AVR between 2004 and June 2010 were divided into two groups: complex AVR (n=50, AVR with ascending aorta replacement in 24 and the Bentall procedure in 26) and simple AVR (n=36). Preoperative characteristics, surgical data, intra- and postoperative allogenic blood transfusion requirement, the postoperative clinical course, and major complications were retrospectively reviewed and compared. Results: The preoperative mean logistic European System for Cardiac Operative Risk Evaluation (%) did not differ between the groups: $11.0{\pm}7.8%$ in the complex AVR group and $12.3{\pm}8.0%$ in the simple AVR group. Although complex AVR required longer cardiopulmonary bypass ($152.4{\pm}52.6$ minutes vs. $109.7{\pm}22.7$ minutes, p=0.001), the quantity of allogenic blood products did not differ ($13.4{\pm}14.7$ units vs. $13.9{\pm}11.2$ units). There was no mortality, mechanical circulatory support, stroke, or renal failure requiring hemodialysis/filtration. No difference was found in the incidence of bleeding (40% vs. 33.3%) which was defined as red blood cell transfusion ${\geq}5$ units, reoperation, or intentional delayed closure. The incidence of mediastinitis (2.0% vs. 0%), ventilator ${\geq}24$ hours (4.0% vs. 2.8%), atrial fibrillation (18.0% vs. 25.0%), mean intensive care unit stay (34.5 hours vs. 38.8 hours), and median hospital stay (8 days vs. 7 days) did not differ, either. Conclusion: AVR combined with additional aortic or root replacement showed an excellent outcome and recovery course equivalent to that after isolated AVR.

• Korean Circulation Journal
• /
• 제53권7호
• /
• pp.425-451
• /
• 2023

Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart diseases, and atrial fibrillation. Non-cardiovascular comorbidities include diabetes mellitus (DM), chronic kidney and pulmonary diseases, iron deficiency and anemia, and sleep apnea. In patients with HF with hypertension and left ventricular hypertrophy, renin-angiotensin system inhibitors combined with calcium channel blockers and/or diuretics is an effective treatment regimen. Measurement of pulmonary vascular resistance via right heart catheterization is recommended for patients with HF considered suitable for implantation of mechanical circulatory support devices or as heart transplantation candidates. Coronary angiography remains the gold standard for the diagnosis and reperfusion in patients with HF and angina pectoris refractory to antianginal medications. In patients with HF and atrial fibrillation, longterm anticoagulants are recommended according to the CHA₂DS₂-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy guidance. In patients with HF and pulmonary disease, beta-blockers are underused, which may be related to increased mortality. In patients with HF and anemia, iron supplementation can help improve symptoms. In obstructive sleep apnea, continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia. Appropriate management of comorbidities is important for improving clinical outcomes in patients with HF.